ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AORT / earnings
PRCT (38) ATEC (34) BVS (61) SGP (43) ⌘ Pro Terminal →

Artivion Inc. (AORT) Next Earnings Date & Expected ±8.8% Move

$23.58 +4.43% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $23.72

Artivion Inc. (AORT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.10B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AORT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Artivion Inc. (NYSE: AORT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $23.58 (+4.43% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, AORT ranks #459 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AORT compare to PRCT and ATEC in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D- (40/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.10B) and ATEC (Alphatec Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AORT?
▼

Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $23.72 (+0.61%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (5)Whales (5)SEC (13)Macro (9)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$51 Bull$22 Base$17 Bear
📬 FREE AORT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AORT)Realized 20D OHLCV Swing Band: ±8.8%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY AORT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 2.46 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 47 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$21.36+8.1% Next Q
Q2 (-2Q)
35
Grade E$23.09-0.6% Next Q
Q3 (-1Q)
37
Grade E$22.94+2.8% Next Q
Current
40
Grade D-$23.58-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AORT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AORT currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.69) and Max Pain ($24.76) forces dealer call-delta covering toward $50.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±8.8% Swing Band

±$2.08 Expected Swing
$21.50 (-8.8%)Spot $23.58$25.66 (+8.8%)
MODEL EARNINGS SETUP GAUGE

AORT Quantitative Pre-Earnings Setup: 40/100

Trailing EPS: $0.20 • YoY Revenue Growth: 13.6%

Model Bullish Setup (40/100)Model Risk Weight (60/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$441.3M$9.8M$839.0K64.4%
FY 20242024-12-31$388.5M-$13.4M$11.0M64%
FY 20232023-12-31$354.0M-$30.7M$18.8M64.4%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AORT)

  • ✓Walkthrough of AORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.63%▲ ASCENDING CHANNEL
2026-11-03O $23.44H $23.58L $22.58C $23.58VOL 627.4K
RES: $38.28SUP: $20.38SMA50: $23.69SMA200: $29.19
$42.25$35.99$29.73$23.48$17.22RES $38.28SUP $20.38$23.582026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AORT Butterfly Map → + Track AORT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AORT)

Health Care Rank #459 of 1015 ⚔️ PRCT vs AORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AORT vs. PRCT, ATEC, BVS, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Artivion Inc. (AORT) ranks #459 by composite RQD confidence (40/100, grade D-) and #343 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AORT at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AORT ACTIVE
Artivion Inc.
D- 40/100 117.0x 64.4% 4.5% +4.43% $1.10B Benchmark Subject
PRCT
PROCEPT BioRobotics Corporation
D- 38/100 — 63.7% -35.0% +1.25% $1.10B /prct-vs-aort →
ATEC
Alphatec Holdings Inc.
E 34/100 — 69.6% -18.4% +3.84% $1.09B /atec-vs-aort →
BVS
Bioventus Inc. (Class A)
C- 61/100 55.0x 68.3% 10.4% -1.31% $1.12B /bvs-vs-aort →
SGP
SpyGlass Pharma Inc.
D- 43/100 — — -35.0% +4.34% $1.08B /sgp-vs-aort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000784199 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artivion Inc. (AORT) reported GAAP revenue of $441.3M (+13.6% vs. FY2024 revenue of $388.5M , and +24.7% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $39.9M, and free cash flow of $839.0K (-92.4% YoY). On the balance sheet, AORT closed FY2025 with $884.8M in total assets against $215.1M in total debt (Altman Z-Score: 2.46, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $441.3M $9.8M $39.9M $839.0K $884.8M $215.1M
FY2024 (FY) 2024-12-31 $388.5M -$13.4M $22.2M $11.0M $789.1M $314.2M
FY2023 (FY) 2023-12-31 $354.0M -$30.7M $18.8M $18.8M — —

3. AORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Artivion Inc. (NYSE: AORT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $23.58 (+4.43% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, AORT ranks #459 in composite RQD confidence.

How does AORT compare to PRCT and ATEC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D- (40/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.10B) and ATEC (Alphatec Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -18.4%, cap $1.09B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AORT?

Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AORT trading relative to its 50-day, 200-day, and 52-week technical levels?

AORT last traded at $23.58 (+4.43% on volume of 626,190 shares), positioning the stock -0.46% below its 50-day simple moving average ($23.69) and -19.22% below its 200-day simple moving average ($29.19). Across its 52-week range of $19.16 to $48.25, AORT sits at the 15.2% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.8% ($21.50 to $25.66).

Direct Sub-Reports: AORT RQD Cockpit AORT 12M Forecast AORT Earnings & Move AORT Dividends & DRIP AORT Insiders & 13F AORT Whale Options AORT Profit Sankey AORT News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AORT — Artivion Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Artivion Inc. (AORT) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $23.58 (+4.43% 1D, market capitalization $1.10B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of 4.5%, gross margin of 64.4%, operating margin of 7.6%, and free cash flow yield of 0.07%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.46, Piotroski F-Score of 9/9, and Debt/Equity of 0.48x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Artivion Inc. (AORT) is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. — for product lines, customer base, or revenue model detail beyond the segment classification. Gross margin is 64.4%, operating margin 7.6%, and net margin 2.2%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Artivion Inc. (AORT) reported $441.3M in annual revenue (up from $388.5M in FY2024, +13.6% YoY) and $9.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($354.0M revenue, -$30.7M net income) through FY2025, AORT scaled operating cash flow to $39.9M and free cash flow to $839.0K, backed by $884.8M in total assets against $215.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.07% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $19.16 – $48.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 117.0x trailing P/E and 19.3x EV/EBITDA against 7.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), AORT carries a macro regime beta of 1.00 and gross margin of 64.4%.

  • Key Question #1: Can AORT sustain or expand its 7.6% operating margin and 4.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $441.3M and free cash flow of $839.0K, how will capital allocation balance growth reinvestment against $215.1M in total debt?
  • Key Question #3: How sensitive is AORT's 98.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AORT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Artivion Inc. (AORT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AORT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AORT Bull vs. Bear Conversation Board — What's Your Call at $23.58?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AORT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AORT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $26.64 (+18.0%)
📌 Pinned Debate

The forensic balance sheet scores 13/20 with Altman Z 2.46, Piotroski F 9/9, and Debt/Equity 0.48, and debt fell from $314.2M to $215.1

Here is why I am bullish on AORT here at $22.58: The forensic balance sheet scores 13/20 with Altman Z 2.46, Piotroski F 9/9, and Debt/Equity 0.48, and debt fell from $314.2M to $215.1M while revenue grew to $441.3M.. Compare AORT's 7.6% operating margin and 4.5% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $21.45 are getting bought.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on 117.0x trailing P/E, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (64.4%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $19.42 (-14.0%)
Spot @ $22.58

Free cash flow fell to $0.8M in FY 2025 and the FCF yield is 0.07% against a trailing P/E of 117, leaving the cash engine pillar at onl

Free cash flow fell to $0.8M in FY 2025 and the FCF yield is 0.07% against a trailing P/E of 117, leaving the cash engine pillar at only 5/20.. Look at the math on AORT: paying 117.0x trailing P/E for 4.5% ROIC and 7.6% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $19.87 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%